Stock Track | Exelixis Soars 5.99% in Pre-market on Analyst Upgrades and Strong Q1 Earnings

Stock Track05-06

Exelixis (EXEL) stock surged 5.99% in pre-market trading on Wednesday, driven by a wave of positive analyst sentiment and the company's robust first-quarter financial results.

Multiple investment firms raised their price targets for the biotechnology company. Wells Fargo increased its target to $40 from $35, Morgan Stanley lifted its target to $50 from $49, Stifel raised its target to $47 from $44, and Goldman Sachs maintained a Buy rating with a $50 price target. TD Cowen was notably bullish, raising its target to $55, citing strength in the CABOMETYX franchise, buyback-driven earnings per share growth, and potential upside from the zanzalintinib pipeline.

The positive analyst moves follow Exelixis's report of strong Q1 2026 results, with revenue of $610.81 million and net income of $210.47 million, indicating improved operational efficiency and margin gains from its oncology portfolio. Investors are also focusing on the regulatory progress of zanzalintinib, for which the U.S. FDA has accepted a New Drug Application with a Prescription Drug User Fee Act date set for December 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155833092?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155833092","market":"us","top_or_hot":-1,"title":"Stock Track | Exelixis Soars 5.99% in Pre-market on Analyst Upgrades and Strong Q1 Earnings","media":"Stock Track","content":"<p>Exelixis (EXEL) stock surged 5.99% in pre-market trading on Wednesday, driven by a wave of positive analyst sentiment and the company's robust first-quarter financial results.</p><p>Multiple investment firms raised their price targets for the biotechnology company. Wells Fargo increased its target to $40 from $35, Morgan Stanley lifted its target to $50 from $49, Stifel raised its target to $47 from $44, and Goldman Sachs maintained a Buy rating with a $50 price target. TD Cowen was notably bullish, raising its target to $55, citing strength in the CABOMETYX franchise, buyback-driven earnings per share growth, and potential upside from the zanzalintinib pipeline.</p><p>The positive analyst moves follow Exelixis's report of strong Q1 2026 results, with revenue of $610.81 million and net income of $210.47 million, indicating improved operational efficiency and margin gains from its oncology portfolio. Investors are also focusing on the regulatory progress of zanzalintinib, for which the U.S. FDA has accepted a New Drug Application with a Prescription Drug User Fee Act date set for December 2026.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Exelixis Soars 5.99% in Pre-market on Analyst Upgrades and Strong Q1 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Exelixis Soars 5.99% in Pre-market on Analyst Upgrades and Strong Q1 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Exelixis (EXEL) stock surged 5.99% in pre-market trading on Wednesday, driven by a wave of positive analyst sentiment and the company's robust first-quarter financial results.</p><p>Multiple investment firms raised their price targets for the biotechnology company. Wells Fargo increased its target to $40 from $35, Morgan Stanley lifted its target to $50 from $49, Stifel raised its target to $47 from $44, and Goldman Sachs maintained a Buy rating with a $50 price target. TD Cowen was notably bullish, raising its target to $55, citing strength in the CABOMETYX franchise, buyback-driven earnings per share growth, and potential upside from the zanzalintinib pipeline.</p><p>The positive analyst moves follow Exelixis's report of strong Q1 2026 results, with revenue of $610.81 million and net income of $210.47 million, indicating improved operational efficiency and margin gains from its oncology portfolio. Investors are also focusing on the regulatory progress of zanzalintinib, for which the U.S. FDA has accepted a New Drug Application with a Prescription Drug User Fee Act date set for December 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXEL","symbol_name":"伊克力西斯","start_time":0,"source_url":"","article_id":"1155833092","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155833092","pubTimestamp":1778076317,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Exelixis (EXEL) stock surged 5.99% in pre-market trading on Wednesday, driven by a wave of positive analyst sentiment and the company's robust first-quarter financial results.Multiple investment...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EXEL":"伊克力西斯"},"translate_title":"个股追踪|Exelixis盘前飙升5.99%，因分析师上调评级和强劲的Q1盈利","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXEL":1},"content_text":"Exelixis (EXEL) stock surged 5.99% in pre-market trading on Wednesday, driven by a wave of positive analyst sentiment and the company's robust first-quarter financial results.Multiple investment firms raised their price targets for the biotechnology company. Wells Fargo increased its target to $40 from $35, Morgan Stanley lifted its target to $50 from $49, Stifel raised its target to $47 from $44, and Goldman Sachs maintained a Buy rating with a $50 price target. TD Cowen was notably bullish, raising its target to $55, citing strength in the CABOMETYX franchise, buyback-driven earnings per share growth, and potential upside from the zanzalintinib pipeline.The positive analyst moves follow Exelixis's report of strong Q1 2026 results, with revenue of $610.81 million and net income of $210.47 million, indicating improved operational efficiency and margin gains from its oncology portfolio. Investors are also focusing on the regulatory progress of zanzalintinib, for which the U.S. FDA has accepted a New Drug Application with a Prescription Drug User Fee Act date set for December 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155833092","isCrawlerRequest":true}